Lumira Capital invests in $33 mln Series B funding of G1 Therapeutics
G1 Therapeutics Inc has raised US$33 million in a Series B financing led by Eshelman Ventures and RA Capital Management. Joining the round were new investors, including Canadian life sciences venture capital firm Lumira Capital. Other investors included Tavistock Life Sciences' Boxer Capital, Hatteras Venture Partners, MedImmune Ventures and Mountain Group Capital. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a pharmaceutical company developing small-molecule therapies to address significant unmet needs in oncology. Its lead program, G1T28, is currently being evaluated in Phase 1a clinical trials.
5 February 2015•3 mins read
